16 August, 2017
Cel-Sci Corporation was upgraded to "neutral" by analysts at Zacks.
After going back and forth with the regulatory agency, Cel-Sci finally got the break it needed, saying on Monday that it had met the FDA's wishes and all clinical trials under an Investigational New Drug application for Multikine are green-lighted again.
Shares of CVM are up about 28% at $2.96 with about two hours left in the trading day on about 10x their average volume over the last two weeks.
The stock of CEL-SCI Corporation (NYSEMKT:CVM) is a huge mover today! The company has market cap of $25.58 million.
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system.
So far, 928 newly diagnosed head and neck cancer patients have been enrolled in the study and all the patients who have completed treatment continue to be followed for protocol specific outcomes, Ergomed said. The FDA has also designated Multikine an Orphan Drug for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (SCCHN).
"Multikine addresses a significant unmet medical need and we look forward to continuing to work with CEL-SCI on what is the largest ever Phase III study in head and neck cancer".
The stock, as of recent close, has shown weekly upbeat performance of 30.43% which was maintained at 24.988% in 1-month period, and is up 78.563% in this year. Shareholders can make better decisions if they focus on target prices, which convey more information for evaluating the potential risk/reward profile of a stock. While the stock price moved along with the volume change, shares are touching $2.81 at the time of writing.
Current levels places CEL-SCI Corporation (:CVM)'s stock about -23.85% from the 50-day high and 92.47% away from the 50-day low. They now have a Dollars 3 price target on the stock.
